N
Google TrendSOCIAL SECURITY 2027 COLA ANNOUNCEMENT (500+) — When will 2027’s Social Security COLA be announced?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:social security 2027 cola announcement500+benfica vs vitória sc200+energy ceasefire200+elliot anderson200+r.c.d. mallorca - u. d. las palmas200+quinyon mitchell2000+tornado north carolina1000+sean young500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "NextPoint Therapeutics" (17 stories)

Top Headline Story

NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors
Lead StoryBusiness Wireworld
Feb 9

NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors

<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxPSG1pdXRUWmJxSTNqMW8zS2hOM3pOMXpDR2xqVkRtZ0ljeEpfekNfbTlwYURkVjgtNnhFeVBpYmZGWnlrTml1RG5mQW5oWWFrbEpSeGJNUGhQSEx6V0g4RFR5ckxlWlQ0WWlSQkd1T1hjMGFaNlRMU2V1OElESDk2Vnl2bk1zTldhTU1nZW0zRFlCR0xMQ1UyOVZ2RWtnM2xCMmVCTlhvcEVneUF6azdjRWkyQmdkTl81cXYyaXRScDlOSElLNmpQWjQxQ0hmb2NTMm0zVDBfMjlJb1R5dlJWbThlaG81SWxpbXc0N0U4dUdDbUJIRXlZRGJMV2xQaFd5YU9iRjRHUG5rOGE1UG9z?oc=5" target="_blank">NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+19m ago

social security 2027 cola announcement

When will 2027’s Social Security COLA be announced?

Filter stories
200+29m ago

benfica vs vitória sc

Benfica tem 'roupa nova' para receber o V. Guimarães: o onze provável

Filter stories
200+29m ago

energy ceasefire

Trump announces partial ceasefire in Ukraine war as Zelenskyy says deal is ‘news to me’

Filter stories
200+29m ago

elliot anderson

James McAtee: How Oliver Glasner has transformed Nottingham Forest midfielder from forgotten man to his new Adam Wharton

Filter stories

Search Results for "NextPoint Therapeutics"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

16 stories displayed
NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
Business Wireworld

NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxNNjZsWEVwQURxRmNuVktyS0hwa3dLUmwyMWdvQkg2Z1ItTmNLOUFBNmxWVTdvSmhqUmpVdzdCZ3RHcDRXcnZCemVCcmZkR0Nod2Rac1k1aWQwQk1kTl9kUnF1SGRraFk4Y3d6Q3psNUptOEQwQzVxWXM1ZDFxWlZfdWlsdVNmUWk4WTBlX2Vjb0dkaThLVUQyNFVqOFNHUERpZFd2WVB5R0ZsdTRWcDZWLVk0d3ctczh0VzdweUpPWG1qRlVuZFZHcWthd01fS3V0OEJzRlVCdE8xSFZoU01uNWd6VVZwNHpkZzRBRjFYbkxRN0tuemc?oc=5" target="_blank">NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
NextPoint Therapeutics
The Pharma Lettergeneral

NextPoint Therapeutics

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE8yeW5fb0szc0dCamdTQVFsaXRFSmczQ0tpM1EtOVJQVTViZE5JVS1tZk4wNE1Vc3NnLWV3ZEt0UEVSQ0FxaEdfMVRDd09GN1p2dEFJZzRMXzNCSjE3N2phaXdaSzRWSDlLS1NHMjRDRDJlbHl2eDVR?oc=5" target="_blank">NextPoint Therapeutics</a>  <font color="#6f6f6f">The Pharma Letter</font>

Read Full StoryMore like this
NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors
BioPharma APACgeneral

NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxOV2JzNjBwRkc5aTVkZU8tWDR1bVItNEt3Z3dOWlBqT010Y2dSVWNkcGlYMlJTaThCeml5bTBfMWlBcGRScm9xbGF0dUgwRXBfX19zYWRrMElfaktRVjJBZWhNMnJIS3Z1anlvV3JzelJHX2ZSLW5wbVphd2xaVkd3S0RMVHhBMnBPc1cyM09OWGhYQWRFNjVhTFZMQmhvYmJYQzZpYW1pX2FYbWxRaW9ISW1OdnBGTlk0bjBlcE5IME8yNnJLOU05S2s4dDFweEIwUWpnTGQ1V3VGWktqQ0pSR2V3?oc=5" target="_blank">NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors</a>  <font color="#6f6f6f">BioPharma APAC</font>

Read Full StoryMore like this
FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb
Pharmaceutical Technologygeneral

FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQOTFsRWR4REMtOERfYl9MR1d0SHlydjNvOW94MVlkal8ybDBlS0l3cU9ZTG11V09zLWstX1Y1UjJiMk5DYVdQVFRZOVZXNFJ0UVBxOHBvOFM4UF9ybXVaYUgxdWVWbEJ5TVRmNWRlYnFWeXlMYUtxZ1c1OGxkdlRENFctYWE5NGtIOHFHekxyUDh1TWhpVlFvNWJmT21fVGJVa2NLU3FhUG1fQ0dVVUE?oc=5" target="_blank">FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb</a>  <font color="#6f6f6f">Pharmaceutical Technology</font>

Read Full StoryMore like this
Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint
Fierce Biotechtech

Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNMWNGM1c3MVVPQ01KajlScVVMYnBxa25hRDZ0U2FQQnhJLUlxUWRrcC1yWm1sTXF1SWZXN3hLNi1uZjRodUdEV18tZ094UEdlci1PUHVWVFFZTEJxUW02NTY0WTRtYy11VWNya0RiQ3hpYVdqSV8zVzdKOFFZTWNIbUZJS0VzNTVZMTVZY2NxZHJDcG5zaTRwaTBoNkd4cVFaNUFiUHdB?oc=5" target="_blank">Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Ivan Cheung
Time Magazineworld

Ivan Cheung

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE80Vm5UT2cyRWZ3Yk5ZR1BDeXl3Sk1rVWp2U2s3QWpvZTBGbVpkb2NUSEg0Xy1pSFV4NlJYTjdjUUNHQ0w4UzVzM3lFVjV0enJSZG93N3JnY1UtMkZNbFlqRjJfemlNSFdZaXhqdUdwX3haQQ?oc=5" target="_blank">Ivan Cheung</a>  <font color="#6f6f6f">Time Magazine</font>

Read Full StoryMore like this
NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno-Oncology Programs:
Sage Journalsworld

NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno-Oncology Programs:

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOdlBXaDNLdmVtdkpsMXZLN2RzUE1wUEc2LWU3azhXdE5rcTRTY2VWMDY4SUpPNGI1YXZocGpuY0MxWTRILUt3SUFNY0QwaVRYbWp5ckI1ZVMtM2VXSWlnMGdlNnBKNjFXaWN4Z2NxWHl1b2wyWllTWldoaHJmczcxTVBtVTdGbkhHNy1RQw?oc=5" target="_blank">NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno-Oncology Programs:</a>  <font color="#6f6f6f">Sage Journals</font>

Read Full StoryMore like this
Eisai's U.S. CEO hired to lead Cambridge cancer biotech
The Business Journalstech

Eisai's U.S. CEO hired to lead Cambridge cancer biotech

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9OVDUxc01ZbWx3dFBuZTk0WjVtUGl6ZG9IaTBST3Bld3k3cm4zSkhPakdDeVM3d0daekZqSlE4UmxLNENNZXVlYzBLZnBnTTZQRzI4cVhlV2tDQ1h4R3E5VE14Q1JSc0lhM3hDeDVwN2dyUExKdmV2MzA0NmI1Zw?oc=5" target="_blank">Eisai's U.S. CEO hired to lead Cambridge cancer biotech</a>  <font color="#6f6f6f">The Business Journals</font>

Read Full StoryMore like this
NPX887 being explored in HHLA2+ solid tumors, including RCC
Urology Timesgeneral

NPX887 being explored in HHLA2+ solid tumors, including RCC

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQQkhpUWRCcDVGLWNuVnBSWWpMQWh3cUxYQXdraWp2S1JrR1BGWVdBWDByTmZzdDlsUWtQb1dINTZjMFFUSTZ1cjFsNUNCYVB3bEFOTUlaU1RtQmNaNkdJc1VvNjFzaG15MHZNU2stdFZMY1FHclVOclQyOUFtSlRuRUJpeGRnUW9vMVpTVTA3dUNiTWFmUWc?oc=5" target="_blank">NPX887 being explored in HHLA2+ solid tumors, including RCC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset
Endpoints Newsgeneral

Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOUXBZM2tzRGpvUlhmakFQekh4aFVac1p2aWlTVmFPcVhZdlQxYWp4N2MzaUhMWHZsTmZzSDJJQ09xanZHM3YwTmhkb3lfdUJrS2QyUGwzLWhoQU9xZkg1YnVGVnUtQzNZbDU0SUFIalVWOVlUQUtEX08tMnpiRlJERDkxZmhEUzh2TG8xSVBWcnVrZnZzSGx6aUdCQ21tTmlwb3VuSXhiaw?oc=5" target="_blank">Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025
Business Wiregeneral

NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025

<a href="https://news.google.com/rss/articles/CBMisgJBVV95cUxORlVKeklUSDJuTWo2WmtSNWxSeE1tdzFaVUZfYU5pS1JBNkJhT0laMmFQdDlHMHBDb2REdEw1cGJrNk1OU1Z1RlRHaV9hVFZRU2tQcWk1bVRWV0tndHBQWkcxZDVPY1hTWTNRaU82OWNtWHJEZ2pCTUlnNVEwYTJwQXV4aERBeXVwTTFUOGJ4cWJtX05aZENwaUdRdW5qOUN1VlZ6aFNETDVKajZCSlFUQ2JRMEltWkRwT3ZKN1hlXzdXVDVUektqRGx5Wm9uR0ZjR2dwMng1aUNKNXUzZUI3bllKM1YwZmtRZW1oWkRjRUhCUWVLZnYwTUlsbkhnUURYSEVPV00xOFVCN3BQeFI4a0w4LXRNTDVIbEFkOXNGQVFiazltSDlCY0Jwd0l1T2Y4LVE?oc=5" target="_blank">NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Sanofi swells venture fund to $750m
Global Venturingworld

Sanofi swells venture fund to $750m

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1rS0dKcE1VX2ZubnJGcVZKWWpQYWQ3N19yb05ucWNneVNLSV8yN1pLOUdXZDF0bzJXVkUyNkRpd3BtbG1CcjR4SkY0WFFWbU1DWllnbDZtSFZNMGluT0R1QWFrUEdCMTBJLW5FVFlqdEFKaGRzYnA4VQ?oc=5" target="_blank">Sanofi swells venture fund to $750m</a>  <font color="#6f6f6f">Global Venturing</font>

Read Full StoryMore like this
After Eisai retirement, Ivan Cheung is back to lead Massachusetts biotech
Fierce Biotechtech

After Eisai retirement, Ivan Cheung is back to lead Massachusetts biotech

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPYm5fQjd5QTZWSVRERjBDTlE0dmdiVzZpbGZtMEVHY2xTc1VneGlWRkJJTGpxOTBVY3MwQVBrWTdXYUNBVXlvM1hjNDMxR2NSV1RKTnlIZGpxLU5KaVlWbS1rd0hGNnlHTXFnWWxFR2tJZG1pM0Q4N1ZWdjIxU2ltTFgwQU5od2RRN3NGNmt0WWp0U2ZCNTI5YWduLUpSdUo4UDJzZlhuNA?oc=5" target="_blank">After Eisai retirement, Ivan Cheung is back to lead Massachusetts biotech</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer
Business Wireworld

NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOQ3hVRkJSOW5NQzFYcTQySXBCOFotVkNNcW0ySmQ1bGdxbkh6ZWMxamdOaHZVNnd4SXBaRTdIa3IwVUZQbVF0X2dUT3lVaDZhdDNPRmk3eWJkNFZjS3Zlek03V2hyWVZUSUdWelc1Q29sZWIwZHk0VHI5X3RIZ1NDa19EREt5LUF6WHprZS1vVUxjeHN6Y3cwNGdzMlZqcE5TUDhsLUxxMktyYUdtZjdERXpJQ21TbUFZSzdNeHlPeEhTcnBPVFE?oc=5" target="_blank">NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Women Leadership in Immuno-Oncology Annual Profile Series: 2025 Edition
Fierce Biotechworld

Women Leadership in Immuno-Oncology Annual Profile Series: 2025 Edition

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOVnJSRWVoOWcyN1NMRjNRZUM2b21PRS05aGJpQXNCNnV1Uk9GeHBNVF9MTWg5LTNwdTZmTkdXTjhoSF9aU0doajZBXzVXZ0F0NElSSDhWM3ktSTZOSkZYSFNGUktzWU53Yk1YZ2tiRmRTVTMwdU5pVGNlV1lxdDFhQW4yTzZoWFhlMUJSZ0ViRzRUa1pLaVZ2Qnd1YUx6UTNJWU5yUjdLajNqYmJXaS1vUDgzTDNpTGZnUXEwQTB3?oc=5" target="_blank">Women Leadership in Immuno-Oncology Annual Profile Series: 2025 Edition</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Chutes & Ladders—Hardy replaces BioMarin’s commercial chief in first big move as CEO
Fierce Biotechgeneral

Chutes & Ladders—Hardy replaces BioMarin’s commercial chief in first big move as CEO

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQOGtZbG00N1Y4cGVCcXR6NEpFY0VqU0h4ZGpRQ3FadGpXOFdSeXZ1UzYtNXF2ZlpGd1BMaGRWNFpoM0lxRWtlS0xEb2szcDdEa25FNTVNNDlNRTlzREJJcjlPeEI3dGl2TXY1THBpV3I5SlFWeU9vdGVQYjM0T3lmMXNMcE45QXlDSXc2WjBUeTJUbjhmdnRJS1huVTBrdlBpX2hFbHVoQ2szX0RpNklvazJ6SQ?oc=5" target="_blank">Chutes & Ladders—Hardy replaces BioMarin’s commercial chief in first big move as CEO</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
"NextPoint Therapeutics" — Live Google News Trends & Headlines